Skip to main content

Sophia Genetics AI

Sophia Genetics said this week that its Sophia AI platform now has radiomics capabilities, which will be combined with the technology's existing genomic analysis capabilties. The new capabilities are based on mechanistic and mathematical modelling and help to predict the evolution of a tumor (size, volume, and location) by analyzing quantitative image features from two or more consecutive standard-of-care medical images (i.e. PET-scans, MRIs, x-rays and more). Clinical proofs of concept have already been executed on hundreds of patients' cases for lung, kidney, glioma, and meningioma, and the technology should soon be applied to any solid tumor, the company said.

The Scan

Rise of B.1.617.2 in the UK

According to the Guardian, UK officials expect the B.1.617.2 variant to soon be the dominant version of SARS-CoV-2 there.

Anne Schuchat to Retire

Anne Schuchat is retiring after more than 30 years at the US Centers for Disease Control and Prevention, Politico reports.

US to Share More Vaccines

CNN reports that the US will share 20 million doses of the Moderna, Pfizer, and Johnson & Johnson SARS-CoV-2 vaccines with other countries.

PNAS Papers on Gene Therapy Platform, Aspergillus Metabolome, Undernutrition Model Microbiome

In PNAS this week: approach to deliver protein-based treatments to cells, pan-secondary metabolome of Aspergillus, and more.